|
Sangamo BioSciences Incorporated, founded in 1995 and based in Richmond, California, develops engineered zinc finger DNA-binding proteins (ZFPs) that regulate gene expression and modification. The firm's ZFP transcription factor, or ZFP TF (TM), technology regulates genes. A ZFP, when linked to a nuclease domain, creates a zinc finger nuclease, or ZFN (TM), used to modify genes. Sangamo BioSciences ZFNs have been used disrupt HIV co-receptor CCR5. ZFP TF and ZFN technologies are marketed under the ZFP Therapeutics (TM) name. The company's ZFP products, in clinical trials, support the treatment of cancer, blocked nerves, diabetic neuropathy, infections, heart disease, pain, and other diseases and conditions. The products also can be used to regulate plant genes. The firm holds multiple U.S. and international patents on its technologies. It also has licensed intellectual property from the Massachusetts Institute of Technology, Johnson & Johnson, the Scripps Research Institute, and Johns Hopkins University. The company has formed strategic alliances with Johnson & Johnson's LifeScan unit, Novo Nordisk, Medarex, Pfizer Incorporated, Novartis, Amgen, Kirin Brewery Company, and Dow AgroSciences Incorporated. Sangamo BioSciences went public in 2000. The firm is listed on NASDAQ under the SGMO symbol. Sangamo BioSciences was founded by Edward Lanphier.
|
Information Sources, Inc.